Wesley Kerr, MD
Epilepsy · Pittsburgh, PANPI 1720506272
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,312 of the $54,315 with a category attached, or 92.6%. 7 manufacturers reported payments, led by SK Life Science, Inc. at 43.7% of the total. 2025 is the largest year on record at $23,159, more than ten times the $207 reported in 2021. Among epilepsy clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $787.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$24K
- Neurelis, Inc.$12K
- UCB, Inc.$8K
- UCB SA$4K
- Jazz Pharmaceuticals Inc.$4K
- Azurity Pharmaceuticals, Inc.$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$50,31293%
- Speaking & faculty fees$1,0202%
- Travel & lodging$1,3322%
- Food & beverage$1,6523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 41 | $23,723 |
| Neurelis, Inc. | 6 | $12,329 |
| UCB, Inc. | 13 | $7,542 |
| UCB SA | 3 | $3,850 |
| Jazz Pharmaceuticals Inc. | 2 | $3,531 |
| Azurity Pharmaceuticals, Inc. | 2 | $2,040 |
| Ceribell, Inc. | 2 | $1,301 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$22,988
- VALTOCO$12,279
- Fintepla$3,964
- Rapid Response EEG$1,210
- Epidiolex$101
How this compares
$54,315 in reported general payments places this provider in the 95th percentile of 28 epilepsy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 14 | $1,760 |
| Oxcarbazepine | 13 | $466 |
| Lamotrigine | 28 | $347 |
| Levetiracetam | 16 | $314 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Pittsburgh
- Alexandra UrbanPittsburgh$25K
- Thandar AungPittsburgh$13K
- Rahiwa GebrePittsburgh$4K
- James CastellanoPittsburgh$3K
- Shobhit SinglaPittsburgh$3K
- Joanna Fong-IsariyawongsePittsburgh$1K
- Anto BagicPittsburgh$1K
- Vijayalakshmi RajasekaranPittsburgh$320
- Maria BaldwinPittsburgh$216
- Joseph TaPittsburgh$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.